Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients With Mild to Moderate Parkinson's Disease on Stable Symptomatic Parkinson's Disease Medication and in Patients With Multiple System Atrophy
Conditions
Interventions
exidavnemab
Placebo Comparator
Locations
7
Poland
Centrum Medyczyne Neuromed Sp. z o.o.
Bydgoszcz, Poland
Krakowska Akademia Neurologii Sp. Z o.o
Krakow, Poland
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Universitari General de Catalunya
Sant Cugat del Vallès, Barcelona, Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain
Start Date
October 24, 2024
Primary Completion Date
August 17, 2026
Completion Date
August 17, 2026
Last Updated
March 10, 2026
NCT07187843
NCT07543861
NCT07545473
NCT05748028
NCT04876339
NCT07495462
Lead Sponsor
BioArctic AB
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions